Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer
- Status
- TERMINATED
- Phase
- PHASE1
Clinical Trials Related to Fulvestrant
Related studies linked through entity extraction aliases.
Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE2
A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy
- Status
- TERMINATED
- Phase
- PHASE4
The Efficacy of Fulvestrant in ESR1(Estrogen Receptor 1) Mutated Metastatic Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) Trial
- Status
- UNKNOWN
- Phase
- PHASE2
TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Palbociclib After CDK and Endocrine Therapy (PACE)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of SY-1365 in Adult Patients With Advanced Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1
This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments
- Status
- COMPLETED
- Phase
- PHASE2
Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1